Researchers conducted a phase 2, double-blind, randomized clinical trial (IRON-HFpEF) at two Dutch centres to assess whether intravenous FCM could improve cardiovascular function and exercise tolerance in patients with HFpEF and iron deficiency without anaemia.

Iron deficiency was resolved in 15 of 20 FCM recipients. Ferritin levels increased from 94 µg/L to 375 µg/L (P < .001), and transferrin saturation increased from 20% to 26% (P = .01).

The study was led by Arno A. van de Bovenkamp of Amsterdam University Medical Center in Amsterdam, Netherlands.

Source: MEDspace